Smoothened Homolog (Protein Gx or SMO) Drugs In Development - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 3, 1 and 2 respectively.

The report outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Report Scope

• The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
• The report reviews Smoothened Homolog (Protein Gx or SMO)) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
• The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Report Coverage

• Smoothened Homolog (Protein Gx or SMO) - Overview
• Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
• Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
• Smoothened Homolog (Protein Gx or SMO) - Dormant Products
• Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
• Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones

Companies Mentioned

• Alfasigma SpA
• F. Hoffmann-La Roche Ltd
• Genentech USA Inc
• Guangdong Zhongsheng Pharmaceutical Co Ltd
• IMPACT Therapeutics Inc
• Kintor Pharmaceutical Ltd
• Mayne Pharma Group Ltd
• Nelum Corp
• Nostopharma LLC
• PellePharm Inc
• Pfizer Inc
• Sun Pharma Advanced Research Company Ltd

For more information about this report visit https://www.researchandmarkets.com/r/jaa84z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900